Johnson & Johnson Cuts Drug Development Time in Half Using AI
Artificial intelligence is already reshaping medicine — and Johnson & Johnson says it’s seeing dramatic results. The healthcare giant has managed to reduce the time needed to identify promising drug candidates by nearly 50%, signaling a major shift in how new treatments are developed.
Speaking at the Reuters Momentum AI event in New York, CIO Jim Swanson explained how AI is accelerating one of the most time-consuming steps in pharmaceutical research: narrowing down potential compounds.
AI Speeds Up, But Doesn’t Replace Discovery
Despite the rapid progress, AI isn’t yet capable of independently discovering and launching new drugs. Instead, it’s being used to scan massive datasets — what Swanson described as the “potential universe” — to identify the most promising chemical compounds and biologics.
The real breakthrough lies in optimization.
“We’ve cut our lead optimization time in half,” Swanson noted, emphasizing that AI is helping researchers move faster without compromising precision.
From Cancer Research to Supply Chains
J&J’s AI push isn’t limited to labs. The company is targeting key areas where the technology can deliver immediate impact, including drug development, AI-powered healthcare products, and supply chain efficiency.
The stakes are high.
“We’re trying to cure cancer,” Swanson said, underlining why the company is aggressively adopting every advanced tool available.
Manufacturing Gets Smarter
Beyond research, AI is also transforming how medicines are produced. The system can now determine optimal conditions — such as when to add solvents and at what temperature — improving consistency and reducing human error in manufacturing processes.
Regulatory Work Shrinks From Hundreds of Hours to Minutes
One of the most striking gains is happening behind the scenes. Preparing regulatory documents for clinical trials has traditionally been a massive task, often taking 700 to 900 hours.
With AI, that workload has been reduced to minutes.
According to Swanson, what once took hundreds of hours can now be completed in roughly 15 minutes — a shift that could significantly speed up the path from lab to market.
AI as a Skill, Not a Replacement
Rather than replacing employees, J&J sees AI as a force multiplier. The company, which employs around 4,000 IT professionals, is focusing on expanding capabilities rather than cutting roles.
Swanson described it as an evolution of skills: engineers and specialists aren’t being replaced — their roles are simply becoming more powerful with AI integration.
A Glimpse Into Pharma’s Future
J&J’s approach highlights a broader industry trend: AI is becoming essential infrastructure in healthcare, not just an experimental tool. While fully AI-created drugs may still be years away, the ability to accelerate every step in the pipeline is already changing the game.
And if current progress continues, the next generation of treatments could arrive faster than ever before.